GLYC Crescent Biopharma Inc.


$ 12.99 nm (nm)    

Thursday, 13-Nov-2025 15:59:52 EST
QQQ $ 608.00 $ -12.68 (-2.04 %)
DIA $ 475.10 $ -8.02 (-1.66 %)
SPY $ 671.97 $ -11.34 (-1.66 %)
TLT $ 89.55 $ -0.74 (-0.82 %)
GLD $ 383.60 $ -3.12 (-0.81 %)
$ 13.05
$ 12.89
$ 12.58 x 500
$ 13.57 x 22
$ 12.72 - $ 13.12
$ 9.81 - $ 44.77
44,666
na
na
$ 1.69
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 glycomimetics-merger-bound-crescent-appoints-joshua-brumm-as-ceo

Crescent also appointed Jonathan McNeill, president and chief operating officer; Ellie Im, M.D., chief medical officer; Rick Sc...

 cantor-fitzgerald-initiates-coverage-on-glycomimetics-with-overweight-rating

Cantor Fitzgerald analyst Eric Schmidt initiates coverage on GlycoMimetics (NASDAQ:GLYC) with a Overweight rating.

 glycomimetics-and-crescent-amend-merger-agreement-crescent-to-own-9690-post-merger-200m-securities-purchase-reallocated-ownership-and-exchange-ratio-unchanged-18m-net-cash-at-closing

- SEC Filing

 glycomimetics-shares-are-soaring-tuesday-heres-why

GlycoMimetics, Inc. (NASDAQ:GLYC) shares are moving higher on Tuesday after the company announced it will merge with Crescent B...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION